Research in Pharmaceutical Sciences

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 15  |  Issue : 4  |  Page : 323--330

The effect of pramlintide, an antidiabetic amylin analogue, on angiogenesis-related markers in vitro


Leila Safaeian1, Golnaz Vaseghi2, Mina Mirian3, Mehdi Firoozabadi1 
1 Department of Pharmacology and Toxicology and Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran
2 Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, I.R. Iran
3 Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran

Correspondence Address:
Leila Safaeian
Department of Pharmacology and Toxicology and Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan
I.R. Iran

Background and purpose: Irregularities of angiogenesis may participate in the pathogenesis of diabetes complications. Pramlintide is an amylin analogue administered for the treatment of type 1 and type 2 diabetes. The present investigation aimed at surveying the effect of pramlintide on angiogenesis-related markers in human umbilical vein endothelial cells (HUVECs). Experimental approach: The proliferation of cells was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) method. The effect of pramlintide on migration was estimated by Transwell® assay. in vitro evaluation of angiogenesis was performed by tube formation assay. The secretion of vascular endothelial growth factor (VEGF) to the supernatant of HUVECs was measured by an enzyme- linked immunosorbent assay (ELISA) kit. All experiments were performed in triplicate. Findings / Results: Pramlintide exhibited no inhibitory effect on HUVECs proliferation. It significantly increased cell migration at the concentration of 1 μg/mL. Pramlintide (1 μg/mL) also enhanced average tubules length, size, and the mean number of junctions. However, there was not any significant change in VEGF release from HUVECs. Conclusion and implications: Findings of this research revealed the effect of pramlintide on angiogenesis- related markers via enhancing migration and tubulogenesis in vitro, suggesting a worthwhile proposition for further clinical researches on improving vascular complications and healing of diabetic wounds.


How to cite this article:
Safaeian L, Vaseghi G, Mirian M, Firoozabadi M. The effect of pramlintide, an antidiabetic amylin analogue, on angiogenesis-related markers in vitro.Res Pharma Sci 2020;15:323-330


How to cite this URL:
Safaeian L, Vaseghi G, Mirian M, Firoozabadi M. The effect of pramlintide, an antidiabetic amylin analogue, on angiogenesis-related markers in vitro. Res Pharma Sci [serial online] 2020 [cited 2020 Nov 29 ];15:323-330
Available from: https://www.rpsjournal.net/article.asp?issn=1735-5362;year=2020;volume=15;issue=4;spage=323;epage=330;aulast=Safaeian;type=0